Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1R | P00736 | 10/20 | 0.70 |
| ▸ | KLK7 | P49862 | 4/20 | 0.62 |
| ▸ | KLK14 | Q9P0G3 | 4/20 | 0.62 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.62 |
| ▸ | CTSG | P08311 | 3/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.62 |
| ▸ | ELANE | P08246 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | KLK1 | P06870 | 1/20 | 0.55 |
| ▸ | C1S | P09871 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914233 | 0.85 | APEX1 (0.67) | C1RKLK7KLK14KLK5CTSG | |
| SCHEMBL914173 | 0.84 | C1R (0.72) | C1RKLK7KLK14KLK5CTSG | |
| SCHEMBL5780185 | 0.83 | C1R (1.00) | C1RKLK7KLK14KLK5CTSG | |
| SCHEMBL7187052 | 0.82 | ALDH1A1 (0.57) | C1RKLK7KLK14KLK5CTSG | |
| SCHEMBL6565178 | 0.78 | ELANE (0.56) | C1RPRSS1ELANEF2PLG | |
| SCHEMBL9984778 | 0.78 | APEX1 (0.76) | C1RKLK7KLK14KLK5CTSG | |
| SCHEMBL18352966 | 0.76 | KLK7 (1.00) | C1RKLK7KLK14KLK5CTSG | |
| SCHEMBL912875 | 0.76 | KLK7 (0.85) | C1RKLK7KLK14KLK5CTSG | |
| SCHEMBL9985390 | 0.76 | C1R (0.70) | C1RKLK7KLK14KLK5CTSG | |
| SCHEMBL18353429 | 0.74 | KLK7 (1.00) | C1RKLK7KLK14KLK5CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003007955-A2 | BIPHENYL APURINIC/APYRIMIDINIC SITE ENDONUCLEASE INHIBITORS TO TREAT CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-01-30 | — | — | WO | claimed |
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | claimed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | disclosed |
| WO-1999048878-A1 | HETEROCYCLIC COMPOUNDS REGULATING CLOTTING | NOVO NORDISK A/S (DK) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | C1R 202/4885KLK7 590/4885KLK14 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.